Effect of pioglitazone treatment on serum chemerin and vaspin levels in polycystic ovary syndrome.


  • Rana Hussein Kutaif Department of Pharmacy, Al-Turath University Collage, Baghdad, Iraq
  • Mustafa G. Alabbassi Department of Pharmacology and Toxicology, College of Pharmacy, University of Alkafeel, Kufa, Iraq
  • Weqar Akram Hussein Obstetrics and Gynaecology Department, College of Al-Kindi medicine / Baghdad University, Baghdad, Iraq
  • Zainab Faleh Ali Obstetrics and Gynaecology Department, Al-Haj Jalal Hospital, Wasit, Iraq
  • Shatha Khayun Jassim Obstetrics and Gynaecology Department, Al-Haj Jalal Hospital, Wasit, Iraq




Adipokines, PCOS, insulin resistance, pioglitazone


Abdominal fat synthesizes a variety of adipokines, including vaspin and chemerin, that affect the resistance to insulin. This research was conducted to demonstrate the effect of pioglitazone, one insulin sensitizer used to decrease insulin resistance, on these adipokines in


obese patients with polycystic ovary (PCOS). Twenty-five obese women with PCOS were treated with pioglitazone 15mg/bid for 12 weeks. Modifications in fasting blood glucose (FBG), serum fasting insulin (FSI), chemerin and vaspin serum levels, follicle stimulation hormone (FSH), luteinizing hormone (LH), testosterone (T), and in baseline and post-therapy were assessed. Body mass index decreased without any substantial variance after 12 weeks of pioglitazone therapy (P> 0.05). T, FSI, HOMA-IR, LH, and FBG levels have decreased considerably (P≤0.01, P≤0.05) after the therapy. No substantial variations were found in FSH (P>0.05). Serum chemerin and vaspin levels were observed no significant difference than before treatment (P>0.05) in obese women with polycystic ovarian syndrome cases.


- Ansam, A. Y.; Manal, K. A.; Bushra J. Al. The Effect of Vitamin D3 and Co-enzyme Q10 Supplementation on Metabolic Biomarkers in Women with Clomiphene Citrate Resistant Polycystic Ovary Syndrome. AJPS. 2018. Vol. 18(2). Pp:142-150. DOI: https://doi.org/10.32947/ajps.v18i2.488

- Tarkun, I.; Dikmen, E.; Cetinarslan, B. and Cantürk, Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw 2010. Vol. 21(4). Pp:272-7.

- Katsiki, N.; Georgiadou, E. and Hatzitolios, AI. The role of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Drugs 2009. Vol. 69. Pp: 1417-31. DOI: https://doi.org/10.2165/00003495-200969110-00001

- Guvenc, Y.; Var, A.; Goker, A.and Kuscu, NK. Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J. Int. Med. Res. 2016. Vol. 44. Pp: 796–805. DOI: https://doi.org/10.1177/0300060516645421

- Ernst, MC.; Issa, M.; Goralski, K.B. and Sinal, C.J. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology. 2010.151. Pp: 1998-2007. DOI: https://doi.org/10.1210/en.2009-1098

- Kaur, J.; Adya, R.; Tan, B.K.; Chen, J.; Randeva, H.S. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. Jan 2010. Vol. 391(4). Pp:1762-8. DOI: https://doi.org/10.1016/j.bbrc.2009.12.150

- Muruganandan, S.; Parlee, S.D.; Rourke, J.L.; Ernst, M.C.; Goralski, K.B.; Sinal, C.J. Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis. J Biol Chem. 2011. Vol. 286(27). Pp:23982-95. DOI: https://doi.org/10.1074/jbc.M111.220491

- Bozaoglu, K.; Bolton, K.; McMillan, J.; Zimmet, P.; Jowett, J.; Collier, G. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology.2007. Vol.148 Pp: 4687-4694. DOI: https://doi.org/10.1210/en.2007-0175

- Tan, B.K.; Chen, J.; Farhatullah, S.; Adya, R.; Kaur, J.; Heutling, D.; Lewandowski, K.C.; O'Hare, J.P.; Lehnert, H.; Randeva, H.S. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes. Sep 2009. Vol.58(9). Pp:1971-7. DOI: https://doi.org/10.2337/db08-1528

- Koiou, E.; Tziomalos, K.; Dinas, K.; Katsikis, I.; Kalaitzakis, E.; Delkos, D.; Kandaraki, E.A.; Panidis, D. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J. 2011. Vol.58 (4). Pp: 237-246. DOI: https://doi.org/10.1507/endocrj.K10E-330

- Weiner, J.; Zieger, K.; Pippel, J. and Heiker, J.T. Molecular Mechanisms of Vaspin Action - From Adipose Tissue to Skin and Bone, from Blood Vessels to the Brain. Adv Exp Med Biol. 2019. Vol. 1111. Pp:159-188. DOI: https://doi.org/10.1007/5584_2018_241

- Kloting, N.; Berndt, J.; Kralisch, S.; Kovacs, P.; Fasshauer, M.; Schon, M. R.; Stumvoll, M.; Blüher, M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun.2006. Vol. 339.Pp: 430-436. DOI: https://doi.org/10.1016/j.bbrc.2005.11.039

- Youn, B.S.; Klöting, N.; Kratzsch, J.; Park, J. W.; Lee, N.; Song, E.S.; Ruschke, K.; Oberbach, A.; Fasshauer, M.; Stumvoll, M.; Blüher, M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008. Vol. 57. Pp: 372- 377. DOI: https://doi.org/10.2337/db07-1045

- Haneen, S. S.; Wassan, A. A.; Suzan, Y. J. Studying Cytotoxic T-lymphocyte- Associated Antigen-4 (CTLA-4) gene Polymorphism in a Sample of Iraqi Women with Polycystic Ovarian Syndrome. AJPS. 2019. Vol.19 (4). Pp:1-6. DOI: https://doi.org/10.32947/ajps.v19i4.626

- Rotterdam ESHRE/ASRM Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004. Vol.19.Pp: 41–47. DOI: https://doi.org/10.1093/humrep/deh098

- Foda, A. A.; Foda, E. A.; El-Negeri, M. A. and El-Said, Z. H. Serum chemerin levels in Polycystic Ovary Syndrome after metformin therapy. Diabetes & Metabolic Syndrome. 2019.Vol.13(2). Pp:1309-1315. DOI: https://doi.org/10.1016/j.dsx.2019.01.050

- Shahebrahimi, K.; Jalilian, N.; Bazgir, N.; and Rezaei, M. Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab. 2016. Vol. 20(6). Pp:805-809. DOI: https://doi.org/10.4103/2230-8210.192925

- Li, X. J.; Yu, Y. X.; Liu, C. Q.; Zhang, W.; Zhang, H. J.; Yan, B.; Wang, L.Y.; Yang, S.Y.; Zhang, S. H. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: A meta-analysis. Clin Endocrinol (Oxf). 2011. Vol. 74. Pp:332-9. DOI: https://doi.org/10.1111/j.1365-2265.2010.03917.x

- Stabile, G.; Borrielli, I.; Artenisio, A. C.; Bruno, L. M.; Benvenga, S.; Giunta, L.; La Marca, A.; Volpe, A.; Pizzo, A. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. Jun 2014. Vol. 27(3). Pp:177-82. DOI: https://doi.org/10.1016/j.jpag.2013.09.015

- Ota, H.; Goto, T.; Yoshioka, T. and Ohyama, N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008. Vol. 90(3). Pp:709-713. DOI: https://doi.org/10.1016/j.fertnstert.2007.01.117

- Sohrevardi, S.M.; Nosouhi, F.; Hossein Khalilzade, S.; Kafaie, P.; Karimi-Zarchi, M.; Halvaei, I.; Mohsenzadeh, M. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. Int J Reprod Biomed (Yazd). 2016. Vol. 14(12). Pp: 743-754. DOI: https://doi.org/10.29252/ijrm.14.12.743

- Ortega-González, C.; Luna, S.; Hernández, L.; Crespo, G.; Aguayo, P.; Arteaga-Troncoso, G.; Parra, A. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005. Vol. 90(3). Pp:1360-1365. DOI: https://doi.org/10.1210/jc.2004-1965

- Wu, Y.; Li, P.; Zhang, D. and Sun, Y. Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. Exp Ther Med. 2018. Vol.15(2). Pp:2120-2127. DOI: https://doi.org/10.3892/etm.2017.5650

- Cho, L.W.; Kilpatrick, E.S.; Keevil, B.G. and Coady, A. M.; Atkin, S.L. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2009. Vol.70 (2). Pp: 233-237. DOI: https://doi.org/10.1111/j.1365-2265.2008.03309.x

- Ghazeeri, G.; Kutteh, W.; Bryer-Ash, M.; Haas, D.; Ke, R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 2003. Vol.79. Pp:562–566. DOI: https://doi.org/10.1016/S0015-0282(02)04843-4

- Romualdi, D.; Guido, M.; Ciampelli, M.; Giuliani, M.; Leoni, F.; Perri, C.; Lanzone. A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- andhyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod. 2003. Vol. 18(6). Pp: 1210–8. DOI: https://doi.org/10.1093/humrep/deg264

- Esteghamati, A.; Ghasemiesfe, M.; Mousavizadeh, M.; Noshad, S.; Nakhjavani, M. Pioglitazone and metformin are equally effective in the reduction of chemerin in patients with type 2 diabetes. J Diabetes Investig. 2014. Vol. 5(3). Pp: 327–332. DOI: https://doi.org/10.1111/jdi.12157

- Stejskal, D.; Karpisek, M.; Hanulova, Z.and Svestak, M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008.Vol. 152(2). Pp:217-21. DOI: https://doi.org/10.5507/bp.2008.033

- Tang, T.; Lord, J.M.; Norman, R.J.; Yasmin, E.; Balen, A. H. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and sub¬fertility. Cochrane Database Syst Rev. 2012. (5). Pp: CD003053. DOI: https://doi.org/10.1002/14651858.CD003053.pub5

- Mahde, A.; Shaker, M.; and Al-Mashhadani, Z. Study of omentin1 and other adipokines and hormones in PCOS patients. Oman Med J. 2009. Vol. 24. Pp: 108–118.

- Cakal, E.; Ustun, Y.; Engin-Ustun, Y.; Ozkaya, M.; Kilinç, M. Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol. 2011. Vol .27. Pp: 491–495. DOI: https://doi.org/10.3109/09513590.2010.501874

- Ibáñez, L.; López-Bermejo, A.; D í az, M.; Enríquez, G.; del Río, L.; de Zegher, F. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol (Oxf). 2009. Vol.71. Pp: 351 – 357. DOI: https://doi.org/10.1111/j.1365-2265.2008.03472.x

- Tan, B.K.; Heutling, D.; Chen, J.; Farhatullah, S.; Farhatullah, S.; Adya, R.; Keay, S.D.; ehnert, H.; Randeva, H.S. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes.2008. 57(6). Pp: 1501–1507. DOI: https://doi.org/10.2337/db08-0127

- Rizos, C.V.; Liberopoulos, E. N.and Mikhailidis, D.P.; Elisaf, M. S. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008. Vol.9. Pp:1087 – 1108. DOI: https://doi.org/10.1517/14656566.9.7.1087

- Ríos-V ázquez, R.; Marzoa-Rivas, R.; Gil-Ortega, I.and Kaski, J.C. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs. 2006. Vol. 6. Pp: 231 – 242. DOI: https://doi.org/10.2165/00129784-200606040-00003

- Kadoglou, N.P.; Kapelouzou, A.; Tsanikidis, H.; Vitta, I.; Liapis, C.D.; Sailer, N. Effects of rosiglitazone /metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011. Vol.119 (2). Pp: 63-68. DOI: https://doi.org/10.1055/s-0030-1265174




How to Cite

Rana Hussein Kutaif, Mustafa G. Alabbassi, Weqar Akram Hussein, Zainab Faleh Ali, & Shatha Khayun Jassim. (2022). Effect of pioglitazone treatment on serum chemerin and vaspin levels in polycystic ovary syndrome. Al Mustansiriyah Journal of Pharmaceutical Sciences, 21(1), 26–33. https://doi.org/10.32947/ajps.v21i1.789